证券代码：600129 证券简称：太极集团 公告编号：2025-068 重庆太极实业（集团）股份有限公司 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 44.88万股 累计已回购股数占总股本比例 0.08% 累计已回购金额 991.85万元 实际回购价格区间 22.01元/股~22.28元/股 关于首次回购股份及回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/7/16，由董事会提议 回购方案实施期限 2025 年 8 月 6 日~2026 年 8 月 5 日 预计回购金额 8,000万元~12,000万元 √减少注册资本 □用于员工持股计划或股权激励 公司将严格按照《上市公司股份回购规则》《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等相关规定，在回购期限 内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事 项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 重庆太极实业（集团）股份有限公 ...

Group 1: Share Buybacks - SF Holding conducted its first share buyback on September 3, 2025, repurchasing 1.185 million A-shares for a total amount of 49.78 million yuan, accounting for 0.02% of the total share capital, with an average price of 42.01 yuan per share [1] - Taiji Group repurchased 448,800 shares on the same day, representing 0.08% of its total share capital, with a total expenditure of 9.9185 million yuan and a price range of 22.01 to 22.28 yuan per share [2] - New Zhonggang repurchased 601,300 shares, which is 0.15% of its total share capital, for a total of approximately 5.26 million yuan, with prices ranging from 8.69 to 8.81 yuan per share [3] Group 2: Strategic Partnerships and Agreements - Tieliu Co. signed a framework agreement with the Yangtze River Delta Hart Robot Industry Technology Research Institute to enhance its capabilities in robot key component design and manufacturing [4] - The company aims to leverage its core advantages in mold development and precision processing to extend its strategic reach into the core components of robotics [4] Group 3: Stock Trading and Suspensions - Tianpu Co. will suspend trading from September 4, 2025, due to multiple instances of abnormal stock price fluctuations from August 22 to September 3, 2025 [5] - The company is conducting a review to protect investor interests in light of these trading anomalies [5] Group 4: Shareholder Changes - Hangzhou High-tech's controlling shareholder has changed to Beijing Jirong Weiye Energy Technology Co., which now holds 19.03% of the company's total shares [7] Group 5: Contracts and Financial Impacts - Robotech's subsidiary signed a significant contract worth approximately 9.465 million euros, which is expected to have a positive impact on the company's financial performance [8] - Jiashun Feihong secured a contract worth about 5.8416 million USD for upgrading South Africa's core railway network, marking a milestone in its overseas projects [9]

证券日报网讯9月3日晚间，太极集团（600129）发布公告称，公司董事会于2025年9月2日收到董事谢友 强先生提交的书面辞职申请。因达法定退休年龄，谢友强先生申请辞去公司董事、董事会审计委员会委 员职务。辞职后，谢友强先生不再担任公司任何职务。 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-068 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2025/7/16，由董事会提议 | | | --- | --- | --- | | 回购方案实施期限 | 2025 年 8 月 6 日~2026 年 8 | 月 5 日 | | 预计回购金额 | 8,000万元~12,000万元 | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 44.88万股 | | | 累计已回购股数占总股本比例 | 0.08% | | | 累计已回购金额 | 991.85万元 | | | 实际回购价格区间 | 22.01元/股~22.28元/股 | | 重庆太极实业（集团）股份有限公司 关于首次回购股份及回购进展的公告 重要内容提示： 一、回购股份的基本情况 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 7 月 16 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-069 重庆太极实业（集团）股份有限公司 关于公司董事退休离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 重庆太极实业（集团）股份有限公司（以下简称：公司）董事会 于 2025 年 9 月 2 日收到董事谢友强先生提交的书面辞职申请。因达 法定退休年龄，谢友强先生申请辞去公司董事、董事会审计委员会委 员职务。辞职后，谢友强先生不再担任公司任何职务。 一、董事离任情况 | （一）提前离任的基本情况 | | --- | | 原定任 | 是否继续在上 | 具体职 | 是否存在未 | 离任原 | 姓名 | 离任职务 | 离任时间 | 期到期 | 市公司及其控 | 务（如适 | 履行完毕的 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 因 | 日 | 股子公司任职 | 用） | 公开承诺 | ...

太极集团公告，公司于2025年9月3日首次回购股份44.88万股，占总股本的0.08%，回购价格在22.01元/ 股至22.28元/股之间，累计已支付总金额为991.85万元。此次回购计划用于注销并减少公司注册资本， 预计回购金额在8000万元至1.2亿元之间，回购期限为2025年8月6日至2026年8月5日。 ...

格隆汇9月3日丨太极集团(600129.SH)公布，2025年9月3日，公司通过集中竞价交易方式首次回购股份 44.88万股，回购股份占公司总股本的比例为0.08%，购买最高价为22.28元/股、最低价为22.01元/股，已 支付的总金额为991.85万元（不含交易费用）。本次回购符合法律法规的有关规定和公司回购股份方案 的要求。 ...

Group 1 - The announcement by the National Medical Products Administration and other authorities regarding the compliance of traditional Chinese medicine (TCM) material production quality management standards is highlighted [2] - Taiji Group Chongqing Fuling Pharmaceutical Factory and Chongqing Traditional Chinese Medicine Slice Factory have conducted audits on their supplier, Zhalantun Tianli Agricultural and Sideline Products Purchase and Sale Co., Ltd., and found it compliant with GAP requirements [2] - A comprehensive evaluation of the TCM materials used by Taiji Group and Chongqing Traditional Chinese Medicine Slice Factory confirmed compliance with the "Traditional Chinese Medicine Material Production Quality Management Standards" [2] Group 2 - The compliance information table indicates that Taiji Group Chongqing Fuling Pharmaceutical Factory produces "Huo Xiang Zheng Qi Oral Liquid" and uses Zhalantun Tianli as a supplier for "Cang Zhu" material [3] - The planting base for "Cang Zhu" is located in Inner Mongolia, with an area of 5060 mu [3] - Chongqing Traditional Chinese Medicine Slice Factory is also involved in the production of "Cang Zhu" slices, confirming the compliance of their material sourcing [3]

Core Viewpoint - The company is focusing on the industrialization of traditional Chinese medicine resources, optimizing its layout across the entire supply chain, and enhancing its core product competitiveness while addressing inventory issues in its key products [1][2]. Group 1: Business Strategy and Product Focus - The company is accelerating the development of traditional Chinese medicine resources, with significant sales growth in major medicinal herbs like Huanglian and Huangqi [1]. - The management has outlined a focus on five key medicinal herb varieties for GAP (Good Agricultural Practices) base construction, with Lianqiao already passing compliance checks [1]. - The company is committed to enhancing its core competitiveness in products, strengthening its industrial marketing system, and developing new products suitable for various sales channels [1][2]. Group 2: Research and Development - The company is concentrating on "4+1" key therapeutic areas, including digestive metabolism drugs, respiratory antibiotics, cardiovascular drugs, narcotic anti-tumor drugs, and health products [2]. - In the first half of the year, the company received 14 authorized patents and submitted applications for three generic drug production and five consistency evaluation production [2]. - The company aims to deepen the integration of research, market, and sales to ensure effective penetration of research capabilities into sales terminals [2]. Group 3: Digital Transformation - The company is advancing its digitalization projects, aiming for a comprehensive upgrade of its operations through AI and data-driven strategies [3]. - The management plans to enhance digital capabilities to improve sales, reduce production costs, and innovate research models [3]. - The company is addressing competition issues with China Traditional Chinese Medicine through various strategies, including asset swaps and joint ventures [3].

Group 1 - The article highlights the latest adjustments in holdings by several large private equity firms in the A-share market as of the end of Q2 2025, revealing significant investment strategies and stock selections [1][2] - Gao Yi Asset's Feng Liu increased positions in New City Holdings and Taiji Group, while also reducing holdings in Hikvision and several material stocks [3][4] - Gao Yi Asset's Dong Xiaofeng added to positions in Zijin Mining and Yun Aluminum, indicating a bullish outlook on the non-ferrous metals sector [4][5] Group 2 - Rui Jun Asset's Dong Chengfei entered the top ten shareholders of Yangjie Technology and Rabbit Baby, reflecting a strategic shift towards semiconductor and building materials [7][8] - Ningquan Asset, led by Yang Dong, also made new investments in Tianhao Energy and increased holdings in Meichang Co., indicating a focus on energy and materials sectors [9][10] - Jinglin Asset increased its stake in Shiji Information, while the Honghu Fund, a joint venture by China Life and Xinhua Insurance, made new investments in China Shenhua and China Petroleum, showcasing a diversified investment approach [11][12][13]